Специфическая адаптивная клеточная иммунотерапия онкогематологических заболеваний и инфекций иммунной системы
Выявлено, что направление миграции ЭБВ специфичных Т клеток в аутологичную ЭБВ-ассоциированную опухоль определяется экспрессией в опухоли специфического антигена ЭБВ и иммунодоминантного рестриктирующего HLA аллеля. С помощью неинвазивного длительного повторного мониторинга введенных ЦТЛ описаны факторы, такие как экспрессия специфического антигена, доминантного HLA аллеля. CCR7 и LFAI молекул… Читать ещё >
Содержание
- Введение.стр
- Глава 1. Обзор научной литературы: Адоптивная клеточная иммунотерапия в онкологии и гематологии. стр
- Предпосылки к развитию адоптивной клеточной иммунотерапии. стр
- Клеточный иммунный ответ. стр
- Методы иммунокоррекции:.стр
- Антиген-специфичная вакцинация. стр
- Адоптивная клеточная иммунотерапия. стр
- Экстракорпоральная активация антиген-специфических Т клеток. стр
- — роль антиген-презентирующих клеток в экстракорпоральной активаили Т лимфоцитов. стр
- — селекция антиген-специфических Т клеток. стр
- Идентификация специфичных антигенов для противовирусного и противоопухолевого ответа. стр
- Факторы, влияющие на эффективность Т клеточного иммунного ответа. стр
- — Миграция Т клеток. стр
- — Отношение числа антиген-специфичных Т клеток к числу клеток мишеней. стр
- — Фенотип эффекторных клеток. стр
- ЫК клетки как компонент НЬА независимого иммунного ответа. стр
- Планирование АКИТ: показания к применению и прогноз. стр
- — Несостоятельность Т клеточного ответа как фактор риска развития заболеваний, подлежащих лечению АКИТ. .стр
- — Клиническое применение АКИТ. стр
- — Прогностические факторы эффективности АКИТ. стр
- — Аутологичные или аллогенные эффекторные клетки. стр
- Глава 2. Материалы и методы. стр
- Клеточные культуры. стр
- Методика управляемой экстракорпоральной активации ЦТЛ .стр.74 стимуляция аллогенными гомозиготными ЭБВ-В-ЛКЛ.стр
- Стимуляция ИАПК. стр
- ЫК клетки. стр
- Генная модификация эффекторных клеток. стр
- Пептиды.стр
- Метод картирования пептидов. стр
- Измерение продукции внутриклеточного .стр
- Определение специфической цитотоксичности
- Т клеток. стр
- Определение уровня предшественников ЦТЛ. стр
- Производство тетрамеров. стр
- Экспериментальные модели опухолей. стр
- Аппаратура.стр
- Клинические исследования. Общая характеристика больных. стр
- Статистический анализ. стр
- Глава 3. Антиген-лрезентируюшие клетки: дифференцированное использование для управляемой стимуляции Т лимфоцитов.—.стр
- 3. 1. Аутологичные ЭБВ-В-ЛКЛ (ЭБВ-В-ЛКЛ) как эффективные АПК для презентации низкоиммуногенных эпитопов. стр
- 3. 2. Аллогенные гомозиготные ЭБВ-В-ЛКЛ.стр
- 3. 3. Искусственные антиген-презентирующие клетки. стр
- Глава 4. Обогащенные антиген-специфичные Т лимфоциты: методы ранней селекции. стр
- 4. 1. Деплеция ЫК клеток. стр
- 4. 2. Ретровирус-обусловленная селекция антиген-специфичных
- Т клеток. стр
- Глава 5. Новые иммуногенные эпитопы вирусов и опухолевых клеток как специфичные антигены для Т клеточного ответа при адоптивной иммунотерапии онкогематологических- иммунных и вирусных заболеваний. стр
- Глава 6. Факторы, влияющие на эффективность Т клеточной адоптивной иммунотерапии. стр
- 6. 1. Изучение специфичности миграции и персистенции ЦТЛ при проведении адоптивной клеточной иммунотерапии. стр
- 6. 2. Определение терапевтической дозы ЦТЛ. стр
- 6. 3. Роль CD4* и CD8″ субпопуляций Т клеток в противоопухолевом/противовирусном ответе антиген-специфичных ЦТЛ. стр
- Глава 7. Активированные НК клетки онкологических больных как эффективный компонент HLA-независимой аутологичной клеточной иммунной терапии солидных опухолей. стр
- Главы 8. Характеристика типа рестрикции Т клеточного ответа к ЭБВ у больных после различных протоколов ТКМ. стр
- Глава 9. Терапевтическая эффективность и безопасность специфической адоптивной клеточной иммунокоррекции у иммунокомпрометированных больных с
- ЭБВ-ЛПЗ и ЦМВ. стр
- 9. 1. Адоптивная иммунотерапия онкогематологических заболеваний неселектированными лейкоцитами доноров. .стр
- 9. 2. Адоптивная иммунотерапия ЭБВ-ЛПЗ. развивающихся у больных после ТКМ. стр
- 9. 3. Адоптивная иммунная терапия с применением антиген-специфичных ЦТЛ в лечении ЭБВ-ЛПЗ.стр
- 9. 4. Адоптивная иммунная терапия с применением антиген-специфичных ЦТЛ в лечении ЦМВ. стр
- Глава 10. Определение прогностических факторов эффективности WT1-специфичной противоопухолевой клеточной терапии и прогностической значимости экспрессии WT1 для прогноза течения заболевания целом. стр
Глава 11: Особенности противоопухолевого клеточного иммунного ответа у онкологических больных и возможности проведения адоптивной противоопухолевой иммунотерапии аутологичными эффекторными клетками.стр.
11.1. Оценка состоятельности WT1 специфичных Т клеток, циркулирующих в организме больных с \Т опухолями.стр.
11.2 Получение УТ1 специфичных ЦТЛ у больных с раком толстого кишечника.стр.
11.3. Изучение особенностей функциональной активности НК клеток больных с М1СА/В+ злокачественными новообразованиями.стр.
Список литературы
- Hansen JA. Gooiey ТА. Martin PJ. Appelbaum F. Chauncey TF. Clift RA. Petersdorf EW: Bone marrow transplantation from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962. 1998
- P. Ehrlich. Ned. Tijdschr. Geneeskd. 5. 273 (1909).
- M. Burnet. Cancer: a biological approach. I. The processes of control. Br Med. J. 5022. 779(1957).
- O. Slutman. Tumor Development after 3-Methylcholanthrene in Immunologically Deficient Athymic-Nude Mice Science 183. 534 (1974).
- V. Shankaran Ikeda H. Bruce AT. White JM. Swanson PE. Old LJ. Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410. 1107 (2001).
- G. P. Dunn. L. J. Old. R. D. Schreiber. The three Es of cancer immunoediting. Armu. Rev. Immunol. 22. 329 (2004).
- Antin JH. Graft-versus-Ieukemia: no longer an epiphenomenon. Blood 1993: 82: 2273−2277
- Weiden, P. L" N. Flournoy. E. D. Thomas. R. Prentice, A. Fefer. С D. Buckner. and R. Storb. 1979. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic -marrow grafts N. Engl. J Med. 300:1068−1073.
- Weiden. P. L. K. M. Sullivan. N. Floumoy. R. Storb, and E. D. Thomas. 1981. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N. Engl. J. Med. 304:1529−1533.
- Frassoni, F., M. Sessarego. A. Bacigalupo, P Strada, M. Repetto. S. Occhini. R. Defferari, and A. Marmont. 1988 Competition between recipient and donor cells after bone marrow transplantation for chronic myeloid leukemia. Br. J. Haematol. 69:47M75.
- Martin, P. J ., J.A. Hansen. R Storb. and ED Thomas 1987. Human marrow transplantation: an immunological perspec- live Adv. Immunol 40 :379 .
- Neudorf. S., A. Filipovich. N. Ramsay, and J. Kersey. 1984. Prevention and treatment of acute graft-versus-host-disease Semin. Hematol. 21 :91.
- Hale. G. S. Cobbold. H. Waldman for Campath-1 users. 1988. T cell depletion with Campath-1 in allogeneic bone marrow transplantation. Transplantation (Baltimore) 45 :753 .
- Maraninchi D. Blaise D. Rio В et al. Impact of T-cell depletion on outcome of allogeneic bone marrow transplantation for standard risk leukemias. Lancet 1987:11: 175−178
- Goldman JM. Gale RP. Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cel! depletion. Ann Intern Med 1988: 108: 806−814
- Horowitz MM. Gale RP. Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990:75: 555−562.
- Ridell S Finding a place for tumor-specific T cells in targeted cancer therapy. J Exp Med. 2004. vol.200. 1533−1537.
- Kurtzman.G., N. Frickhofen, J. Kimball. D.W. Jenkins, AW. Nienhuis, and N.S. Young. 1989. Pure red cell aplasia of 10 years' duration due to persistent Parvovirus BI9 infection and its cure with immunoglobulin therapy.N. Engl. j Med. 321:519.
- Rickinson A. Moss D. Human cytotoxic T lymphocyte responses to Epstein- Barr virus infection. Annu Rev Immunol. 1997:15:405−431
- O’Reilly R. Small T, Papadopoulos E, Lucas K, Lacerda J. Koulova L. Biology and adoptive cell therapy of Epstein-Barr virus associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev. 1997:157:195−216
- Lim JB, Kwon OH. Kim HS, Kim HO, Choi JR. Provenzano M. Stroncek D. Adoptive immunotherapy for cytomegalovirus (CMV) disease in immunocompromised patients. Yome> M"/J2004.45:S18−22. 22. Brennan DC Cytomegalovirus in renal transplantation J Am SQC Nephrol 2001−12:848−55.
- Pouria S. State Oi. WongW. Hendry BM, CMV infection is associated with transplant renal artery stenosis. QJM 1998:91:18−9.
- Hosenpud JD. Coronary artery disease after heart transplantation and its relation ot cytomegalovirus. Am Heart J 999−138:S469−72.
- Ljungman P. Engelhard D. Link H. et al. 'treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immunoglobulin: experience of European Bone Marrow Transplant Group. Clin Infect Dis. 1992−14:83l-835.
- Boeckh M. Bowden RA, Gooley T. Myerson D, Corey L. Successful modification of a pp65 anti-genemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic transplant recipients. Blood. 1999−93: 1781−1782.
- Krause H. Hebart H, Jahn G, Mueller CA. Einsele H. Screening for CMV- specific T-cell proliferation to identify patients at risk of developing late-onset CMV disease Bone Marrow Transplant. 1997:19: 1111−1116.
- Stuge ТВ. Holmes SP. Saharan S. Tueltenberg A. Roederer M, Weber JS. Lee PP: Diversity and Recognition Efficiency of T Cell Responses to Cancer. Plos Med 2004. I: e28.
- Kolb HJ. Mittermu «Her J. Ciemm Ch el al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990- 76: 2462−2465.
- Ba „г ВМАМ. Schattenberg A. Mensink EJBM et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Cltn Oncol 1993- 11: 513−519.
- Porter DL. Roth MS. McGarigle С el al. induction of graft versus- host disease as immunotherapy for relapsed chronic myeloid leukemia. New Engl J Med 1994- 330: 100−106.
- Kolb HJ. Schattenberg A. Goldman JM el al. Graft-versusleukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995: 86: 2041−2050.
- Collins RH. Shpilberg O. Drobyski WR el al Donor leukocyte infusions in 140 patients with relapsed malignant.-) niter allogeneic bone marrow transplantation J Clin Oncol 1997- 15:433−444.
- Kolb HJ. Schattenberg A. Goldman JM. et al Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995:86:2041−50.
- Collins RH. Jr. Shpilberg O. Drobyski WR. et al Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997:15:433−44.
- Falkenburg JH. Wafelman AR. Joosten P. et al Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999:94:1201 -8.
- Marijt WA. Heemskerk MH, Kloosterboer FM, et al Hemaiopoiesis-restricted minor histocompatibility antigens HA-l-or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 2003- 100:2742-
- Goulmy. E. 1988 Minor histocompatibility antigens in man and their role in transplantation. Transplant. Rev. 2:29−53.
- Goulmy. E. A. Termijtelen. B. A Bradley, and J. J. van Rood. 1977. Yantigen killing by T cells of women is restricted by HLA. Nature (Lond.). 266:544−545.
- Goulmy. E., J. W. Gratama, E. Blokland, F. E. Zwaan. and J. J. van Rood. 1983. A minor transplantation antigen detected by МИС-restricted cytotoxic T lymphocytes during graft-versus-host disease. Nature (Lond). 302:159−161.
- Janeway, C.A. Jr., Walport, M. & Shlomchik, M.J. Immunobiohgy- e (ln. 5 (Garland Publishing, New York, 2001).
- Banchereau, J. & Steinman, R.M. Dendritic cells and the control of immunity. Nature 392. 245−252 (1998).
- Pardoll. D.M. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2. 227−238 (2002).
- Stoll, S., Delon. J. Brotz. T.M. & Germain. R.N. Dynamic imaging of T cell- dendritic cell interactions in lymph nodes. Science 296. 1873−1876 (2002)
- Sun 0 ' Pollok KE. Burton RL. et al. Simultaneous ex vivo expansion of cytomegalovirus and Fpslein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65. Blood 1999:94: 3242−3250.
- Latouche JB. Sadelain M. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol. 2000 Apr: l 8(4}:405−9.
- Lenschow DJ. Walunas TL. Bluestone JA. CD28/B7 system of T cell costimulation Annu Rev Immunol. 1996:14:233−58. Review.
- Wijnaendts L. Le Deis! F. Griscelli C. Fischer A Development of immunologic functions after bone marrow transplantation in 33 patients with severe combined immunodeficiency. Blood. 1989 Nov l:74(6):22I2−9.
- Keenan RD, Ainsworth J. Khan N, Bruton R, Cobbold M, Assenmacher M, Milligan DW. Moss PA. Br J Haematol. Purification of cytomegaiovirus-specific CD8 T cells from peripheral blood using HLA-peptide tetramers.2001 Nov-ll5(2):428−34.
- Iezzi G. Karjalainen K. Lanzavecchia A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity. 1998 Jan-8{l):89−95.
- Faber LM, van Luxemburg-Heijs SAP, Willemze R. Falkenburg JHF. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical donor of a patient with leukemia. J Exp Med 1992: 176: 1283−1289
- Cheever MA. Chen W (1997) Therapy with cultured T cells: principles revisited. Immunol Rev 157:177−194
- Dudley ME. Wunderlich JR. Robbins PF et al (2002) Cancer regression and autoimmunity in patients after clonal rcpopulation with antitumor lymphocytes. Science 298 850−854.
- KAMMULA US. MARINCOLA FM: Cancer immunotherapy: is there real progress at last? Biodrugs 11:249−260. 1999.
- Mocellin S. Mandruzzato S. Bronte V. Lise M. Nitti D (2004) Part I: vaccines for solid tumours. Lancet Oncol 5:681−689
- Friedmann-Morvinski D. Bendavid A. Waks T. Schindler D, Eshhar Z: Redirected primary T-cells harboring a chimeric receptor require co-stimulation for their antigen-specifi с activation. Blood 2004.
- Jensen. MC. Cooper. L) and Wu. AM el al. (2003) Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cyloiheiapy. 5. pp. 131−8.
- Cooper. LJ. Al-Kadhimi. Z and DiGiusto. D et al. (2004) Development and application of CD19-specific T cells for adoptive immunotherapy of В ceil malignancies. Blood Cells Mol Dis. 33. pp. 83−9.
- Gonzalez. S. Naranjo. A and Serrano. LM et al. (2004) Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma. J Gene Med, 6, pp. 704−11.
- Kahlon. KS. Brown. С and Cooper. LJ et al. (2004) Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 64. pp. 9160−6.
- Cooper, UN. Kalos. M and DiGiusto. DL et al. (2005) T-cell genetic modification for re-directed tumor recognition. Cancer Chemother Biol Response Modifiers. 22. pp. 293−324.
- STANC0VSK1 I. SCHINDLER DC, WAKS T, YARDEN Y. SELA M. ESHHAR Z: Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol 15!: 6577−6582. 1993.
- Holler PD. Chlewicki LK, Kranz DM: TCRs with high affinity for foreign pMHC show self-reactivity. Nat Immunol 2003, 4:55−62.
- Berger CL, Longley J, Hanlon D, Girardi M, Edelson R. The clonotypic T cell receptor is a source of tumor-associated antigens in cutaneous T cell lymphoma. Ann N Y Acad Sci 2001−941:106−22.
- Nelson EL. Li X, Hsu FJ, et al Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell. non-Hodgkin's lymphoma. Blood 1996−88:580−9.
- Pinilla-lbarz J, Cathcart K. Korontsvit T. et al Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000:95:1781−7.
- Greenberg PD. Yee C. Warren EH. Gavin M. Topp M, Cooper L, Nelson B. Ohlen C. Riddell SR: Therapy of human viral and malignant diseases with gene-modified T cell clones European Cytokine Network 2000, 11:304−305.
- Berger С Blau CA, Huang ML. luliucci JD, Daigamo DC, Gaschet J, Heimfeld S, Clackson T. Riddell SR: Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood 2004. 103:1261−1269.
- VAN DER BRUGGEN P, TRAVERSARI C, CHOMEZ P. LURQU1N C. DE PLAEN E. VAN DER EYNDE B, KNUTH A. BOON T: A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma. Science 254: 1643−1647, 1991.
- SAHIN U. TURECI O, SCHMITT H, COCHLOVIUS B, JOHANNES T. SCHM1TS R. STENNER F, LUO G, SCHOBERT I. PFREUNDSCHUH M: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92: 11 810−11 813, 1995.
- Ohminami H. Yasukawa M. Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for w’l’l peptide. Blood 2000:95:286−93.
- Oka Y. Elisseeva OA. Tsuboi A. et al Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WTl) product. Immunogenetics 2000−51:99−107.
- Gao L. Bellantuono I, Elsasser A, et al Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WTl. Blood 2000−95:2198−203.
- Call KM, Glaser T. Ito CY. et al Isolation and characterization of a zinc finger polypeptide gene at the human chromosome II Wilms' tumor locus. Cell 1990−60:509−20.
- Maurer U, Brieger J, Weidmann E, Mitrou PS, Hoelzer D, Bergmann L. The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. Exp Hematol 1997−25:945−50.
- Miwa H, Beran M, Saunders GF. Expression of the Wilms* tumor gene (WTl) in human leukemias. Leukemia (Baltimore) 1992−6:405−9.
- Inoue K. Ogawa H. Sonoda Y. et al Aberrant overexpression of the Wilms tumor gene (WTl) in human leukemia. Blood 1997:89:1405−12
- Inoue K, Sugiyama H. Ogawa H. et al WTl as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 199:84:3071−9.
- Cilloni D. Gottardi E, Messa F, et al Significant correlation between the degree of WTl expression and the International Prognostic Scoring System Score in patients with myelodysplasia syndromes. J Clin Oncol 2003:21:1988−95.
- Ueda T. Oji Y, Naka N. et al Overexpression of the Wilms' tumor gene WTl inhuman bone and soft-tissue sarcomas Cancer Sci 2003−94:271−6.
- Oji Y, Miyoshi S. Maeda H, et al Overexpression of the Wilms' tumor gene WTl in de novo lung cancer. Int J Cancer 2002−100:297−303.
- Miyoshi Y. Ando A, Egawa C, et al High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 2002−8:1167−71.
- Makifa M, Hiraki A, Azuma T, et at Antilung cancer effect of WT!-specific cytotoxic T lymphocytes. Clin Cancer Res 2002−8:2626−31.
- Wang P. Munger CM, Joshi AD, Pirruccello SJ, Joshi SS. Cytotoxicity of cord blood derived Her2/neu-speciflc cytotoxic T lymphocytes against human breast cancer in vitro and in vivo. Breast Cancer Res Treat. 2004 Jan-83(l): 15−23
- Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Slevanovic S. SYFPE1TH1: database for MHC ligands and peptide motifs. Immunogenetics 1999−50:213−9.
- Kern F, Surel IP. Faulhaber N. el al. Target structures of the CD8+ T-cell response to human cytomegalovirus: the 72-kilodalton major immedmteearly protein revisited. J Virol. 1999−73:8179−8184.
- Kent F. Faulhaber N. Froemmel C. et al. Analysis of CDS T-cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. EurJImmunoI. 2000−30: 1676−1682
- Palmer DC. Balasubramaniam S. Hanada К el al (2004) Vaccine-slimulaled. adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J Immunol 173:7209−7216
- Vitale M. Pelusi G, Taroni В et al (2005) HLA class 1 antigen down- regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res 11:67−72
- Romero JM, Jimenez P. Cabrera T et al (2005) Coordinated downregulation of the antigen presentation machinery and HLA class l/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int J Cancer 113:605−610
- Saio M, Teicher M. Campbell G. Feiner H. Delgado Y, Frey AB (2004) Immunocytochemical demonstration of down regulation of NLA class-1 molecule expression in human metastatic breast carcinoma. Clin Exp Metastasis 21:243−249
- Knutson KL, Wagner W, Disis ML Adoptive T cell therapy of solid cancers. Cancer Immunol Immunolher. 2006 Jan-55(l):96−103. Epub 2005 Oct 27. Review.
- Chang CC, Campoli M, Ferrone S (2003) Hl. A class I defects in malignant lesions: what have we learned? Keio J Med 52:220−229
- Campbell, J. J., S. Qin, D. Unutmaz, D. Soler, K. E. Murphy. M. R. Hodge, L. Wu, E. С Butcher. 2001. Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol 166:6477.
- Liyanage UK. Moore TT, Joo HG et al (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma J Immunol 169:2756−2761
- Curiel TJ, Coukos G, Zou L. et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 942−949
- Viguier M. Lemaitre F. Verola О et al (2004) Foxp3 expressing CD4-KTD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173:1444−1453
- Jones E. Dahm-Vicker M. Simon AK et al (2002) Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreaciivity in mice. Cancer Immun 2:1
- CurielTJ. Wei S, Dong H ctal (2O03) Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity Nat Med 9:562−567
- Almand B. Clark Jl, Nikitina E et al (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166:678−689
- Dudley ME. Wunderlich J. Nishimura MI, et al. (2001) Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 24:363−373
- Topalian SL. Muul LM. Solomon D, Rosenberg SA: Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. Journal of Immunological Methods 1987. 102:127−141.
- Ho WY. Blattman JN, Dossett ML, Yee C, Greenbcrg PD: Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 2003, 3.431−437.
- Riddell SR. Greenberg PD: The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human aniigen-specific T cells. Journal of ImmunologicalMethods 1990, 128:189−201.
- Kunzmann V. Wilhelm M. Anti-lymphoma effect of gammadelta T cells. 1. euk Lymphoma. 2005 May-46(5):671−80. Review.
- Knutson KL, Disis ML (2005) Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol lmmunother DOl:10.!007/s00262−004−0653−2.2005-On-Line.
- Dudley ME. Wunderlich JR, Yang JC et al (2002) A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J lmmunother 25:243−251
- Dudley. M.E. et al. 2001.. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. lmmunother 24:363−373.
- Dudley, M.E. et al. 2002.. A phase 1 study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J lmmunother 25:243−251.
- Korf, J., Veenma-van der Duin, L“ Brinkman-Medema, R, Niemarkt, A. & de Leij, L.F. Divalent cobalt as a label to study lymphocytes distribution using PET and SPECT. J. Nucl. Med 39, 836−841 (1998).
- Gobuty. A. H-. Robinson. R.G. & Barth, R.F. Organ distribution of 'WmTc- and 5lCr-labeled autologous peripheral blood lymphocytes in rabbits. J. Nucl Med 18. 141−146(1977).
- Lewin, M. et at. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 18, 410−414 (2000).
- Dodd, C.H. et at. Normal T-cell responses and in vivo magnetic resonance imaging of T-cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticles. У Immunol Methods 256, 89−105 (2001).
- Schelper. R.L. & Adrian, E.K Jr. Monocytes become macrophages: they do not become microglia: a light and electron microscopic autoradiographic study using 125-iododeoxyuridine. J Neuropalhol. Exp. Neurol. 45, 1−19 (1986).
- Blasberg. R.G. ei at Imaging brain tumor proliferative activity with l24l.iododeoxyuridine. Cancer Res 60. 624−635 (2000)
- Tjuvajev, J.G. et at. Imaging of brain tumor proliferative activity with iodine- 131-iododeoxyuridine. J. Nucl Med 35, 1407−1417 (1994).
- Tjuvajev, J.G. et ai. Imaging the expression of transfected genes in vivo. CancerRes. 55,6126−6132(1995).
- Tjuvajev, J.G. el al. Noninvasive imaging cif herpes virus thymidine kinase gene transfer and expression- a potential method for monitoring clinical gene therapy. Cancer Res 56,4087095(1996).
- Larson, S.M. Tjuvajev, J & Blasberg, R. Triumph over mischance: a role for nuclear medicine in gene therapy. J. Nuci Med. 38, 1230−1233(1997).
- Tjuvajev, J.G. et al. imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res 58, 4333−4341 (1998).
- Costa, G.L. e! al. Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T-cell delivery of the IL-12 p40 subunit. J Immunol 167.2379−2387(2001).
- Дубровин M.M. Неинвазивная визуализация гемопоэтических и опухолевых клеток с использованием молекулярно-биологических методов (экспериментальное обоснование и клинические исследования) Автореферат к диссертации Москва. 2006 г.
- Biron. А. К. В. Nguyen, G. Pien, L. P. Cousens. Т. P. Salazar-Mather. 1999. Natural killer cells in antiviral defense: function and regulation by innate cytokines Ann» Rev Immunol 17:189.
- Diefenbach. A., D. H. RauSet. 2002. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol. Rev. 188:9.
- Kiessling. R., G. Bataillon, E. W. Lamon. E. Klein. 1974. The lymphocyte response fo primary Moloney sarcoma virus tumors: definition of a nonspecific component of the in vitro cellular hypo reactivity of tumor-bearing hosts./и/ J Cancer 14:642.
- Herberman. R. B" M. E. Nunn, D. H. Lavrin. 1975. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer 16:216.
- Ljunggren, H. G" K. Karre. 1990. In search of the «missing self: MHC molecules and NK cell recognition. Immunol Today 11:237.
- Groh. V. S. Bahram, S. Bauer, A. Herman, M. Beauchamp, T. Spies. 1996. Cell stress-regulated human major histocompatibility complex class I gene expressed in gaslroinleslinal epithelium. Prvc. Nail Acad. Sci USA 93:12 445.
- Cerwenka, A. J. L. Baron. L. L. Lanier. 2001. Ectopic expression of retinoic acid early inducible-. gene (RAE-I) permits natural killer cell-mediated rejection of a MHC class 1-bearing tumor in vivo. Proc Natl Acad Sci USA 98:11 521.
- Groh. V. R. Rhinehart. J. Randolph-Habecker. M. S. Topp. S. R. Ridded. T. Spies. 2001. Costimulation of CD8
- Sivori. S. M. Vitale. L. Morelli. L. Sanseverino. R. Augugliaro. C. Bottino. 1. Moretta. A. Moretta. 1997. p46. a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med. 186:1129.
- Robertson. M. J. 2002. Role of chemokincs in the biology of natural killer cells./. Leukocyte Biol. 71:173
- Rossi. D. A. Zlotnik. 2000. The biology of chemokines and their receptors Annu Rev Immunol. 18:217.
- Robertson. M. J. B. T. Williams. K. Christopherson. Z. Brahmi, R. Hromas. 2000. Regulation of human natural killer cell migration and proliferation by the exodus subfamily of CC chemokines. Cell Immunol 199:8.
- Walz. A. R. Burgener. B. Car. M. Baggiolini. S. L. Kunkel. R. M. Strieter. 1991. Structure and neutrophil-aciiv-ii.iig piiwmos ofa novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med. 174:1355.
- Li. A. S. Dubey. M L. Varney. B. J. Dave. R. K. Singh. 2003. IL-8 directly enhanced endothelial cell survival. proliferation. and matrix metal ioproteinase production and regulated angiogenesis. J Immunol 170:3369.
- Vihinen. P. V. M. Kahari. 2002. Matrix metal loproteinases in cancer: prognostic markers and therapeutic targets .In! .1 Cancer 99:157.
- Levy, A. T» V. Cioce. M. E. Sobei. S. Garbisa. W. F. Grigioni, L. A. Liotta, W. G. Stetler-Stevenson. 1991. Increased expression of the M, 72.000 type IV collagenase in human colonic adenocarcinoma. Cancer Res 51:439.
- MacDougall. J. R. M. R. Bani. Y Lin. J. Rak. R. S. Kerbel. 1995. The 92- kDa gelatinase В is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells. Cancer Res. 55:4174.
- Salih. H. R. H. G. Rammensee. A. Steinle. 2002. Cutting edge: down- regulation of MICA on human tumors by proteolytic shedding ./ Immunol 169:4098.
- Hale G, Slavin S. Goldman JM. Mackinnon S. Giralt S. Waldmarm H. Alemtuzumab (Campath-IH) for treatment of lymphoid malignancies in the age of nonmyeloaNative conditioning? Bone Marrow Transplant. 2002 Dec-30(l2):797−804
- Hale G., Waldmann H. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T cell depleted marrow transplants. CAMPATH users. Blood, 1998- 91:3079−3083.
- AnrJerlini P. Korbling M The use of mobilized peripheral blood stem cells from normal donors for allografting Stem Cells. 1997:15:9−17
- Sirvent N, Reviron D, deLamballerie X, Michel G. First report of Epstein- Barr virus lymphoproliferative disease after cord blood transplantation. Bone Marrow Transplant. 2000:25:120−121
- Ohga S. Kanaya Y. Maki H, et al. Epstein-Barr virus-associated lymphoproliferative disease after a cord blood transplant for Diamond-Blackfan anemia. Bone Marrow Transplant. 2000:25:209−212
- Fisher A. Severe combined immunodeficiencies. Immunodef Rev. 3:83, 1992.
- Gatti RA. Alien HD. Meeuwissen HJ, Hong R, Good RA: Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 2:1366, 1968
- De Koning J, Dooren LJ, van Bekkum DW, van Rood JJ, Dicke KA, Radl J: Transplantation of the bone marrow cells and fetal thymus in an infant with lymphopenic immunological deficiency. Lancet 1:1223. 1969.
- Kenny AB. Hitzig WH: Bone marrow transplantation for severe combined immunodeficiency disease. Eur J Paediatr 131:155,1979
- O’Reilly RJ. Brochstein J. Dinsmore L. Kirkpatrik D: Marrow transplantation for congenital disorders Semin Hematol 21:188.1984
- Fischer A. Friedrich W, Levinsky R, Vossen J. Griscelli C. Kubanek B. Morgan G. Wagermakcr G, Landais P: Bone marrow transplantation for immunodeficiency and osteopetrosis. European survey 1968−1985. Lancet 1:1080. 1986
- Buckley RH, Schiff SE. Schiff RI. Marker! ML, Williams LW, Roberts JL. Myers LA. Ward FE: Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency N Engl J Med 340:508. 1999
- Buckley RH. Schiff SE, Schiff RI. Roberts JL. Markert ML. Peters W, Williams LW. Ward FE: Hapl о identical stem cell transplantation in human severe combined immunodeficiency Semin liematol 30:92.1993 (suppl 4)
- Knobloch C. Friedrich W. T cell receptor diversity in severe combined immunodeficiency following HLA-hapl о identical bone marrow transplantation. Bone Marrow Transplant. 1991 Nov-8(5):383−7
- Chu E, Umetsu D. Rosen F. Geha RS. Major histocompatibility restriction of antigen recognition byT cells in a recipient of haplotype mismatched human bone marrow transplantation.. J Clin Invest. 1983 Sep:72(3):l 124−9.
- RIDDELL SR. GREENBERG PD: Cellular adoptive immunotherapy after bone marrow transplantation. Cancer TrcaiRes 76: 337−369. 1995.
- BRODIE SJ. LEWINSOHN DA. PATTERSON BK, JIYAMAPA D, KRIEGER J. COREY L. GREENBERG PD. RIDDELL SR: In vivo migration and function of transferred HlV-l-specific cytotoxic T cells. Nature Med5: 34−41,1999.
- Blatlman J Greenberg P Cancer Immunotherapy: a Treatment Ibr thi: Masses Science. Jul 2004, vol 305. 200−205.
- Gaiger A. Carter L. Greinix H. et al WTI-specific serum antibodies in patients with leukemia. Clin Cancer Res 200l-7(Suppl):761s-5s.
- Elisseeva OA, Oka Y, Tsuboi A, et al Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies Blood 2002,99:3272−9.
- Scheibenbogen C, Letsch A, Thiel E, et al CDS T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002,100:2132−7.